Can I read A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC on EtoBox?

A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC by Lei Wang; Yongzhong Luo; Shengxiang Ren; Zhihong Zhang; Anwen Xiong; Chunxia Su; Jin Zhou; Xinmin Yu; Yanping Hu; Xiaodong Zhang; Xiaorong Dong; Shuyan Meng; Fengying Wu; Xiaoming Hou; Yuanrong Dai; Weifeng Song; Baiyong Li; Zhongmin Maxwell Wang; Yu Xia; Caicun Zhou is a Medicine article available to read on EtoBox.

What is A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC about?

## PURPOSE: This study aimed to evaluate the safety and efficacy of ivonescimab (a bispecific antibody against programmed death-1 [PD-1] and vascular endothelial growth factor [VEGF]) as first-or second-line monotherapy in advanced immunotherapy naïve non-small-cell lung cancer (NSCLC) patients. ## METHODS: Eligible patients received intravenous ivonescimab 10mg/kg every 3 weeks (Q3W), 20 mg/kg every 2 weeks (Q2W), 20 mg/kg Q3W or 30mg/kg Q3W. The primary endpoints were safety and objective response rate (ORR) per RECIST v1.1. ## RESULTS: At data cutoff (October 5, 2022), 108 patients were enrolled and received ivonescimab. Programmed death ligand-1 (PD-L1) tumor proportion score (TPS) was ≥1% in 74 (68.5%) patients, including 35 (32.4%) with TPS ≥50%. The median follow-up was 10.4 months (range 8.4 to 10.9 months). For all patients, ORR and disease control rate (DCR) were 39.8% and 86.1%, respectively. ORR by TPS was 14.7%, 51.4% and 57.1% in patients with TPS <1%, ≥1%, and ≥50%, respectively. In the 67 PD-L1 positive patients receiving first-line ivonescimab, the ORR was 33.3%, 52.6%, 60.0%, and 75.0% at the doses of 10mg/kg Q3W, 20 mg/kg Q2W, 20 mg/kg Q3W and 30mg/kg Q3W, respec

Who reads A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC?

Author

Lei Wang; Yongzhong Luo; Shengxiang Ren; Zhihong Zhang; Anwen Xiong; Chunxia Su; Jin Zhou; Xinmin Yu; Yanping Hu; Xiaodong Zhang; Xiaorong Dong; Shuyan Meng; Fengying Wu; Xiaoming Hou; Yuanrong Dai; Weifeng Song; Baiyong Li; Zhongmin Maxwell Wang; Yu Xia; Caicun Zhou

Publisher

Elsevier BV

Published

2024

Language

EN

Field

Medicine (Health Sciences)